HDAC inhibitors in kidney development and disease

Pediatric Nephrology

Volumn 28, Issue 10, 2013, Pages 1909-1921

  Brilli, Lauren L ^a   Swanhart, Lisa M ^a   De Caestecker, Mark P ^b   Hukriede, Neil A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

HDACi; Histone deacetylase; Kidney development; Kidney regeneration; Renal disease; Renal injury

Indexed keywords

BEVACIZUMAB; ENTINOSTAT; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; ISPINESIB; PANOBINOSTAT; RECOMBINANT INTERLEUKIN 2; RIDAFOROLIMUS; ROMIDEPSIN; SORAFENIB; VALPROIC ACID; VORINOSTAT;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; KIDNEY DEVELOPMENT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; PRIORITY JOURNAL; REVIEW;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; KIDNEY; KIDNEY DISEASES; ORGANOGENESIS; TREATMENT OUTCOME;

EID: 84883303698     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2320-8     Document Type: Review

References (116)

1. Chen S, Bellew C, Yao X, Stefkova J, Dipp S, Saifudeen Z, Bachvarov D, El-Dahr SS (2011) Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J Biol Chem 286:32775-32789
2. Bush EW, McKinsey TA (2010) Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 106:272-284
3. Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23
4. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101:1241-1246
5. Smith CL (2008) A shifting paradigm: histone deacetylases and transcriptional activation. Bioessays 30:15-24
6. Nusinzon I, Horvath CM (2005) Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci STKE 2005:re11
7. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17-31
8. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32-42
9. Chen S, El-Dahr SS (2012) Histone deacetylases in kidney development: implications for disease and therapy. Pediatr Nephrol. doi: 10.1007/s00467-012- 2223-8
10. Stanya KJ, Kao HY (2009) New insights into the functions and regulation of the transcriptional corepressors SMRT and N-CoR. Cell Div 4:7
11. Watson PJ, Fairall L, Santos GM, Schwabe JW (2012) Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 481:335-340
12. Li X (2011) Epigenetics and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 1812:1213-1218
13. Yoshida M, Matsuyama A, Komatsu Y, Nishino N (2003) From discovery to the coming generation of histone deacetylase. Curr Med Chem 10:2351-2358
14. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Tandy W, Mazitschek R (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243
15. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458
16. Davie JR (2003) Inhibition of histone deacetylase activity by butyrate. J Nutr 133:2485S-2493S
17. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90
18. Bieliauskas AV, Pflum MK (2008) Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 37:1402-1413
19. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4921
20. Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA (1975) Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc Natl Acad Sci U S A 72:1003-1006
21. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003-3007
22. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351-1356
23. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
24. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
25. Jain S, Zain J (2011) Romidepsin in the treatment of cutaneous T-cell lymphoma. J Blood Med 2:37-47
26. de Groh ED, Swanhart LM, Cosentino CC, Jackson RL, Dai W, Kitchens CA, Day BW, Smithgall TE, Hukriede NA (2010) Inhibition of histone deacetylase expands the renal progenitor cell population. J Am Soc Nephrol 21:794-802
27. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S (2009) Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297:F996-F1005
28. Arany I, Herbert J, Herbert Z, Safirstein RL (2008) Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells. Am J Physiol Renal Physiol 294:F577-F581
29. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321:892-901
30. Shein NA, Grigoriadis N, Alexandrovich AG, Simeonidou C, Lourbopoulos A, Polyzoidou E, Trembovler V, Mascagni P, Dinarello CA, Shohami E (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J 23:4266-4275
31. Dong G, Wang L, Wang CY, Yang T, Kumar MV, Dong Z (2008) Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. J Pharmacol Exp Ther 325:978-984
32. Arany I, Clark JS, Ember I, Juncos LA (2011) Epigenetic modifiers exert renal toxicity through induction of p66shc. Anticancer Res 31:3267-3272
33. Mulder GJ, Meerman JH (1983) Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N, O-sulfonation in chemical carcinogenesis of aromatic amines. Environ Health Perspect 49:27-32
34. Ornoy A (2009) Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 28:1-10
35. Nervi C, Borello U, Fazi F, Buffa V, Pelicci PG, Cossu G (2001) Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res 61:1247-1249
36. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30:61-72
37. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson EN (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118:3588-3597
38. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672-2681
39. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN (2007) Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21:1790-1802
40. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479-488
41. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467-8476
42. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555-566
43. Pillai R, Coverdale LE, Dubey G, Martin CC (2004) Histone deacetylase 1 (HDAC-1) required for the normal formation of craniofacial cartilage and pectoral fins of the zebrafish. Dev Dyn 231:647-654
44. Yamaguchi M, Tonou-Fujimori N, Komori A, Maeda R, Nojima Y, Li H, Okamoto H, Masai I (2005) Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development 132:3027-3043
45. Noel ES, Casal-Sueiro A, Busch-Nentwich E, Verkade H, Dong PD, Stemple DL, Ober EA (2008) Organ-specific requirements for Hdac1 in liver and pancreas formation. Dev Biol 322:237-250
46. Farooq M, Sulochana KN, Pan X, To J, Sheng D, Gong Z, Ge R (2008) Histone deacetylase 3 (hdac3) is specifically required for liver development in zebrafish. Dev Biol 317:336-353
47. Drummond I (2003) Making a zebrafish kidney: a tale of two tubes. Trends Cell Biol 13:357-365
48. Cartry J, Nichane M, Ribes V, Colas A, Riou JF, Pieler T, Dolle P, Bellefroid EJ, Umbhauer M (2006) Retinoic acid signalling is required for specification of pronephric cell fate. Dev Biol 299:35-51
49. Wingert RA, Selleck R, Yu J, Song HD, Chen Z, Song A, Zhou Y, Thisse B, Thisse C, McMahon AP, Davidson AJ (2007) The cdx genes and retinoic acid control the positioning and segmentation of the zebrafish pronephros. PLoS Genet 3:1922-1938
50. Menegola E, Di Renzo F, Broccia ML, Giavini E (2006) Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res C Embryo Today 78:345-353
51. Dressler GR (2009) Advances in early kidney specification, development and patterning. Development 136:3863-3874
52. Reidy KJ, Rosenblum ND (2009) Cell and molecular biology of kidney development. Semin Nephrol 29:321-337
53. Sharma M, Brantley JG, Vassmer D, Chaturvedi G, Baas J, Vanden Heuvel GB (2009) The homeodomain protein Cux1 interacts with Grg4 to repress p27 kip1 expression during kidney development. Gene 439:87-94
54. Rosenberg SL, Chen S, McLaughlin N, El-Dahr SS (2011) Regulation of kidney development by histone deacetylases. Pediatr Nephrol 26:1445-1452
55. Song R, Van Buren T, Yosypiv IV (2010) Histone deacetylases are critical regulators of the renin-angiotensin system during ureteric bud branching morphogenesis. Pediatr Res 67:573-578
56. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB (2005) Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 16:667-675
57. Yoshikawa M, Hishikawa K, Marumo T, Fujita T (2007) Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 18:58-65
58. Chen JK, Chen J, Thomas G, Kozma SC, Harris RC (2009) S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 297:F585-F593
59. Advani A, Huang Q, Thai K, Advani SL, White KE, Kelly DJ, Yuen DA, Connelly KA, Marsden PA, Gilbert RE (2011) Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol 178:2205-2214
60. Gilbert RE, Huang Q, Thai K, Advani SL, Lee K, Yuen DA, Connelly KA, Advani A (2011) Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int 79:1312-1321
61. Iwano M, Neilson EG (2004) Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 13:279-284
62. Li JH (2002) Smad7 Inhibits Fibrotic Effect of TGF- on Renal Tubular Epithelial Cells by Blocking Smad2 Activation. J Am Soc Nephrol 13:1464-1472
63. Zeisberg M, Neilson EG (2010) Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21:1819-1834
64. Noh H, Oh EY, Seo Y, Yu MR, Kim YO, Ha H, Lee HB (2009) Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor- b1-induced renal injury. Am J Physiol Renal Physiol 297:F729-F739
65. Imai N, Hishikawa K, Marumo T, Hirahashi J, Inowa T, Matsuzaki Y, Okano H, Kitamura T, Salant D, Fujita T (2007) Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury. Stem Cells 25:2469-2475
66. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, Krofft RD, Logar CM, Marshall CB, Ohse T, Shankland SJ (2008) Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 296:F213-F229
67. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Verbeelen D, van Grunsven LA, Van den Branden C (2011) Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol 22:1863-1875
68. Pang M, Zhuang S (2010) Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 335:266-272
69. Chen J, Chen JK, Nagai K, Plieth D, Tan M, Lee TC, Threadgill DW, Neilson EG, Harris RC (2012) EGFR signaling promotes TGFbeta-dependent renal fibrosis. J Am Soc Nephrol 23:215-224
70. Kuratsune M, Masaki T, Hirai T, Kiribayashi K, Yokoyama Y, Arakawa T, Yorioka N, Kohno N (2007) Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology (Carlton) 12:565-571
71. Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T (2010) Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 298
72. Kinugasa F, Noto T, Matsuoka H, Urano Y, Sudo Y, Takakura S, Mutoh S (2010) Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl Immunol 23:18-23
73. Nelson PJ, Rees AJ, Griffin MD, Hughes J, Kurts C, Duffield J (2012) The renal mononuclear phagocytic system. J Am Soc Nephrol 23:194-203
74. Cao Y, Semanchik N, Lee SH, Somlo S, Barbano PE, Coifman R, Sun Z (2009) Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci U S A 106:21819-21824
75. Xia S, Li X, Johnson T, Seidel C, Wallace DP, Li R (2010) Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 137:1075-1084
76. Fan LX, Li X, Magenheimer B, Calvet JP, Li X (2011) Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81:76-85
77. Park EY, Woo YM, Park JH (2011) Polycystic kidney disease and therapeutic approaches. BMB Rep 44:359-368
78. Van Bodegom D, Saifudeen Z, Dipp S, Puri S, Magenheimer BS, Calvet JP, El-Dahr SS (2006) The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression. J Biol Chem 281:31234-31244
79. Fan LX, Li X, Magenheimer B, Calvet JP (2012) Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81:76-85
80. Marumo T, Hishikawa K, Yoshikawa M, Fujita T (2008) Epigenetic regulation of BMP7 in the regenerative response to ischemia. J Am Soc Nephrol 19:1311-1320
81. Villanueva S, Cespedes C, Vio CP (2006) Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 290:R861-R870
82. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, Sampath TK (1998) Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102:202-214
83. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S (2002) Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13(Suppl 1):S14-S21
84. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964-968
85. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q (2004) The renal papilla is a niche for adult kidney stem cells. J Clin Invest 114:795-804
86. Oliver JA, Klinakis A, Cheema FH, Friedlander J, Sampogna RV, Martens TP, Liu C, Efstratiadis A, Al-Awqati Q (2009) Proliferation and migration of label-retaining cells of the kidney papilla. J Am Soc Nephrol 20:2315-2327
87. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M, Kristiansen G (2008) Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381
88. Mund C, Lyko F (2010) Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays 32:949-957
89. Epping MT, Bernards R (2009) Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol 41:16-20
90. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32:157-165
91. Marks PA (2010) Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799:717-725
92. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA (2009) The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 13:2376-2385
93. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL, Hsiao PW (2009) Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 15:840-850
94. Kwon HK, Ahn SH, Park SH, Park JH, Park JW, Kim HM, Park SK, Lee K, Lee CW, Choi E, Han G, Han JW (2009) A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells. Biol Pharm Bull 32:1723-1727
95. Juengel E, Engler J, Mickuckyte A, Jones J, Hudak L, Jonas D, Blaheta RA (2010) Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int 105:549-557
96. Juengel E, Dauselt A, Makarevic J, Wiesner C, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA (2012) Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett:83-90
97. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M (2011) Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncol Res 19:217-223
98. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M (2010) Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. Urology 76(764):e767-713
99. Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R (2009) Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 40:10-29
100. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589-3597
101. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193
102. Berg WJ, Schwartz LH, Amsterdam A, Mazumdar M, Vlamis V, Law TM, Nanus DM, Motzer RJ (1997) A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15:353-355
103. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R (2005) Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11:3535-3542
104. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM (2005) Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 11:3558-3566
105. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106:77-84
106. Lin F, Moran A, Igarashi P (2005) Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest 115:1756-1764
107. Kobayashi T, Terada Y, Kuwana H, Tanaka H, Okado T, Kuwahara M, Tohda S, Sakano S, Sasaki S (2008) Expression and function of the Delta-1/Notch-2/Hes-1 pathway during experimental acute kidney injury. Kidney Int 73:1240-1250
108. Terada Y, Tanaka H, Okado T, Shimamura H, Inoshita S, Kuwahara M, Sasaki S (2003) Expression and function of the developmental gene Wnt-4 during experimental acute renal failure in rats. J Am Soc Nephrol 14:1223-1233
109. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (2008) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26:795-797
110. Wong CC, Cheng KW, Rigas B (2012) Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther 341:572-578
111. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912-3922
112. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507-519
113. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA (2006) A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 5:57-60
114. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR (2012) A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. doi: 10.1007/s10637-012-9812-z
115. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA (2011) A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 29:451-455
116. Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, Lau CC, Adamson PC, Blaney SM (2011) Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res 17:589-597